In T2DM patients with severe renal failure and HbA1cabove target, either a DPP4 inhibitor or a GLP-1RA (if eGFR 15–30 mL/min/1.73 m2) may be considered to improve blood glucose control. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.